Stock Analysis on Net
Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Analysis of Revenues

Microsoft Excel

Revenues as Reported

Merck & Co. Inc., income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Pharmaceutical segment sales 53,583 52,005 42,754 43,021 41,751
Animal Health segment sales 5,625 5,550 5,568 4,703 4,393
Other segment sales — — — 23 175
Segment sales 59,208 57,555 48,322 47,747 46,319
Other 907 1,728 382 247 521
Sales 60,115 59,283 48,704 47,994 46,840

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Sales Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Merck & Co. Inc. sales increased from 2021 to 2022 and from 2022 to 2023.